Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion
Introduction
Cigarette smoking during pregnancy has been associated with spontaneous abortion, placental pathology, preterm labor, low birth weight, stillbirth, sudden infant death syndrome, and childhood developmental problems [1]. Approximately 13% of mothers report smoking during the last 3 months of pregnancy [2], and many find it hard to stop or reduce smoking without the aid of medication. The benefits of smoking cessation during pregnancy include significant increase in birth weight and reduction in risk of preterm birth, as well as long-term health benefits to both mother and child [3].
Currently, there is no approved medical therapy for smoking cessation during pregnancy. Occasionally health care providers recommend the use of nicotine replacement therapy (NRT) for those pregnant women who desire to quit smoking and fail other non-pharmacotherapeutic interventions. However, maternal exposure to nicotine has also been associated with risk to the developing fetus and newborn. Prenatal exposure to nicotine in animals was associated with blunted newborn respiratory response and increased rate of death [4]; anxiety, hyperactivity, and cognitive impairment in offspring [5]; and vasoconstriction related to decreased uteroplacental blood flow [6]. In humans, congenital malformations were higher among women who used NRT (patch, gum, or inhaler) during the first trimester than with nonsmokers [7]. Due to concern over safety of the developing fetus exposed to NRT, the goal of investigations in our laboratory is to evaluate an alternative to NRT for smoking cessation during pregnancy.
Bupropion is an antidepressant used successfully for smoking cessation in non-pregnant patients [8]. Accordingly, bupropion may also offer therapeutic benefit for smoking cessation in pregnant patients. However, its safety as a medication to be used during pregnancy remains unclear. Bupropion is labeled as Category C by the US Food and Drug Administration (i.e., data from animal models revealed adverse effects and there are not adequate studies in humans), but potential benefits may warrant its use during pregnancy despite potential risks [9].
Preclinical investigations in our laboratory on the biodisposition of bupropion by human placenta revealed that it crosses from the maternal-to-fetal circulation [10], and that it is metabolized by placental tissue [11]. Placental transfer of bupropion from the maternal-to-fetal circulation was approximately 20% [10]. This is less than the 30–40% reported transfer of nicotine which diffuses freely across the placental tissue [12], [13], [14]. The lower placental transfer of bupropion could be explained, in part, by the activity of placental efflux transporters. We have demonstrated that efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) have an active role in the efflux of their substrates across placental apical membrane [15]. Bupropion may be a P-gp substrate, as suggested by its stimulation of ATP hydrolysis by P-gp expressing membranes [16]. However, a direct determination of its transport by P-gp and/or other transporters expressed in placental apical membrane has not been reported to date.
An earlier report from our laboratory provided evidence that bupropion is metabolized by placental tissue during its perfusion [11]. The major metabolites of bupropion (threo- and erythro-hydrobupropion) formed by the placental tissue were distinct from the major hepatic metabolite (OH-bupropion), suggesting the placenta has a unique role in regulating the metabolic fate of bupropion. However, since bupropion is extensively metabolized to OH-bupropion, with plasma metabolite levels exceeding those of the parent compound [17], this active metabolite will be present in the circulation of pregnant patients receiving bupropion for treatment. Thus, concern over potential fetal exposure to OH-bupropion should be taken into consideration and the role of the placenta in its biodisposition warrants further investigation.
Taken together, the goals of this investigation were to determine the role of the placenta in the active regulation (metabolism, efflux transport) of OH-bupropion disposition compared to its parent compound, bupropion. Information obtained will be necessary for evaluating the extent of fetal exposure to bupropion and OH-bupropion, and consequently the safety of bupropion as an alternative medication for smoking cessation therapy in pregnant patients.
Section snippets
Chemicals
All chemicals were purchased from Sigma–Aldrich (St. Louis, MO) unless otherwise mentioned. The murine monoclonal antibodies C219 and BXP-21 were purchased from Signet Laboratories (Dedham, MA). Actin (C-2) mouse monoclonal antibodies and goat anti-mouse horseradish peroxidase-conjugated antibody were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). [14C]-hydroxybupropion (specific activity, 56.9 mCi/mmol) was custom-synthesized by Synthese AptoChem Inc. (Montreal, Canada). [3
P-gp and BCRP expression in human placenta
P-gp protein expression was determined in 200 individual samples of human placental brush border membranes. There was a positive correlation between P-gp and BCRP protein expression in human placenta (Fig. 1 , p < 0.001).
Bupropion and OH-bupropion transport by P-gp and BCRP
The transport of bupropion was ATP-dependent and partially inhibited in the presence of 600 μM verapamil (selective for P-gp mediated transport) and 25 nM KO143 (selective for BCRP). The kinetic parameters of its transport were: P-gp, K t = 0.5 ± 0.2 μM bupropion and V max = 6 ± 0.7
Discussion
The goal of this investigation was to determine human placental biodisposition of OH-bupropion, including metabolism and efflux by active transporters, in comparison to its parent compound bupropion. Previous reports from our laboratory and others revealed that bupropion is extensively metabolized by placental tissue [11] and appears to be a substrate of placental efflux transporters [16]. This led us to hypothesize that the placenta “actively regulates” the maternal–fetal distribution of
Acknowledgements
The authors thank the Perinatal Research Division for their assistance, and the Publication, Grant, & Media Support of the UTMB Department of Obstetrics and Gynecology. Supported by the National Institute on Drug Abuse Grant R01DA024094 to TN.
References (31)
Tobacco and pregnancy
Reprod Toxicol
(2009)If nicotine is a developmental neurotoxicant in animal studies dare we recommend nicotine replacement therapy in pregnant women adolescents?
Neurotoxicol Teratol
(2008)- et al.
Bupropion metabolism by human placenta
Biochem Pharmacol
(2010) - et al.
Transplacental transfer biotransformation studies of nicotine in the human placental cotyledon perfused in vitro
Life Sci
(1998) - et al.
Effects of nicotine-specific antibodies Nic311 Nic-IgG on the transfer of nicotine across the human placenta
Biochem Pharmacol
(2005) - et al.
Behavioral and biochemical investigations of bupropion metabolites
Eur J Pharmacol
(2003) - et al.
Permeation of astilbin taxifolin in Caco-2 cell their effects on the P-gp
Int J Pharm
(2009) - et al.
Misclassification of maternal smoking status and its effects on an epidemiologic study of pregnancy outcomes
Nicotine Tob Res
(2007) - et al.
Interventions for promoting smoking cessation during pregnancy
Cochrane Database Syst Rev
(2004) - et al.
Maternal tobacco smoking nicotine replacement neurobehavioural development
Acta Paediatrica
(2008)
Direct effects of nicotine on contractility of the uterine artery in pregnancy
J Pharm Exper Ther
Smoking habits nicotine use congenital malformations
Obstet Gynecol
A comparison of sustained-release bupropion placebo for smoking cessation
N Engl J Med
Transplacental transfer and metabolism of bupropion
J Matern Fetal Neonatal Med
Cited by (25)
Drug therapy in pregnant and nursing women
2021, Atkinson's Principles of Clinical PharmacologyPlacental control of drug delivery
2017, Advanced Drug Delivery ReviewsCitation Excerpt :An interesting modulator of BCRP expression is hypoxia [86]. Drugs that are known substrates of BCRP include zidovudine, tenofovir disoproxil fumarate, bupropion, nitrofurantoin, and glyburide, to name a few [52,80,82,87,88]. Many of the substrates of BCRP are also substrates of P-gp, demonstrating redundancy in placental efflux capacity.
Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid
2016, American Journal of Obstetrics and GynecologyCitation Excerpt :Therefore OHBUP is thought to be the major contributor to the pharmacologic activity of bupropion.10-12 Ex vivo studies using dual perfusion of placental lobule demonstrated that bupropion and OHBUP cross the human placenta.13,14 Moreover, in vitro experiments showed that bupropion is metabolized by placental tissue, with TB being the major placental metabolite of bupropion.15
Drug Therapy in Pregnant and Nursing Women
2012, Principles of Clinical Pharmacology, Third EditionPharmaceutical drug transport: The issues and the implications that it is essentially carrier-mediated only
2011, Drug Discovery TodayCitation Excerpt :Secondly, comparison of the data in Table 1 and Fig. 1 of [75] enables one to identify which (11) of the 55 drugs are claimed to be uptake (seven) or efflux (four) transporter substrates and which (44) are thus supposedly taken up ‘passively’. Of these 44, we can find clear literature evidence (see also [10]) for the carrier-mediated transport of 18 of them, namely acebutolol [76], acyclovir [77], atenolol [78], bretylium [79–81], bupropion [82], cefuroxime [83], chlorothiazide [84,85], gabapentin [86,87], hydrocortisone (cortisol) [88,89], ketoprofen [90], mannitol [91,92], methylprednisolone [93,94], phenytoin [95–97], progesterone [98], propranolol [99], testosterone [100] and trimethoprim [101]. The assumption that these molecules cross membranes only ‘passively’ is, therefore, incorrect.
Characterization of the Stereoselective Disposition of Bupropion and Its Metabolites in Rat Plasma and Brain
2023, European Journal of Drug Metabolism and Pharmacokinetics